WebMD Medical News
Daniel J. DeNoon
Louise Chang, MD
May 29, 2012 -- Women should not use hormone therapy (HT) to prevent chronic conditions, such as bone loss, after menopause.
The advice is the draft recommendation of the U.S. Preventive Services Task Force (USPSTF). It does not apply to women using hormone therapy to treat menopausal symptoms such as hot flashes.
"We are just looking at women without symptoms who are trying to prevent something bad from happening in the future," the leader of the task force's HT analysis, Kirsten Bibbins-Domingo, MD, PhD, tells WebMD. Bibbins-Domingo is associate professor of medicine at the University of California, San Francisco.
The task force made its recommendation after reviewing an analysis of the latest HT research by Heidi D. Nelson, MD, MPH, and colleagues at Oregon Health & Science University.
"The last time the task force looked at this, they discouraged use of HT for any chronic condition," Nelson tells WebMD. "And in the real world, there may be some women who took HT for menopausal symptoms and are wondering whether to stay on it. These findings really apply to using HT after the symptoms of menopause are over."
The updated analysis relies heavily on the now-famous Women's Health Initiative (WHI) study in which older, mostly postmenopausal women received either a placebo or HT. In that trial, treated women got a form of estrogen called conjugated equine estrogen (CEE, derived from horse urine) plus progestin. Women who had undergone hysterectomy received estrogen (CEE) alone.
Hormone therapy clearly had some benefits in preventing chronic conditions. Women getting estrogen plus progestin had:
Women getting estrogen alone had:
But hormone therapy had clear harms as well. Women getting estrogen plus progestin had:
"On balance, weighing the benefits against the harms led us to say we would not use these therapies for the prevention of chronic conditions," Bibbins-Domingo says. "It really doesn't work for most of the conditions we considered. And for the biggest benefit, osteoporosis, the harms far outweigh that benefit."
The panel took into account the fact that other effective ways to prevent osteoporosis are available.
Here's the exact language of the draft recommendations:
The draft recommendations are posted on the USPSTF web site. Anybody who would like to post comments and/or recommend changes is welcome to do so. After considering these comments, the USPSTF will issue its final recommendations.
What will that mean?
The USPSTF is an independent panel of experts in preventive and family medicine. Members are appointed for a four-year term. Their job is to evaluate medical evidence for preventive medicine. Topics are nominated by the public and chosen by the panel.
USPSTF recommendations do not set policy, although they may serve as the basis for guidelines established by medical associations and insurers.
Under the Affordable Care Act, Medicare and health plans must pay for services recommended by the USPSTF. Medicare may pay for services not recommended by USPSTF if the Department of Health and Human Services so decides. Insurers may or may not reimburse for services not recommended by the USPSTF.
The Nelson team's review of the evidence regarding preventive use of HT appears in the May 28 issue of Annals of Internal Medicine.
SOURCES:Nelson, H.D. Annals of Internal Medicine, May 28, 2012.Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Draft Recommendation Statement, May 29, 2012.Kirsten Bibbins-Domingo, MD, PhD, USPSTF topic lead on HT; associate professor of medicine and of epidemiology and biostatistics, University of California, San Francisco.Heidi D. Nelson, MD, MPH, research professor of medical informatics, clinical epidemiology, and medicine, Oregon Health & Sciences University, Portland.
Here are the most recent story comments.View All
The views expressed here do not necessarily represent those of KOKI FOX23 - Tulsa
The Health News section does not provide medical advice, diagnosis or treatment. See additional information.